BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 29486782)

  • 1. Improve dosimetric outcome in stage III non-small-cell lung cancer treatment using spot-scanning proton arc (SPArc) therapy.
    Li X; Kabolizadeh P; Yan D; Qin A; Zhou J; Hong Y; Guerrero T; Grills I; Stevens C; Ding X
    Radiat Oncol; 2018 Feb; 13(1):35. PubMed ID: 29486782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improve the dosimetric outcome in bilateral head and neck cancer (HNC) treatment using spot-scanning proton arc (SPArc) therapy: a feasibility study.
    Liu G; Li X; Qin A; Zheng W; Yan D; Zhang S; Stevens C; Kabolizadeh P; Ding X
    Radiat Oncol; 2020 Jan; 15(1):21. PubMed ID: 32000817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spot-Scanning Proton Arc (SPArc) Therapy: The First Robust and Delivery-Efficient Spot-Scanning Proton Arc Therapy.
    Ding X; Li X; Zhang JM; Kabolizadeh P; Stevens C; Yan D
    Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1107-1116. PubMed ID: 27869083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small-spot intensity-modulated proton therapy and volumetric-modulated arc therapies for patients with locally advanced non-small-cell lung cancer: A dosimetric comparative study.
    Liu C; Sio TT; Deng W; Shan J; Daniels TB; Rule WG; Lara PR; Korte SM; Shen J; Ding X; Schild SE; Bues M; Liu W
    J Appl Clin Med Phys; 2018 Nov; 19(6):140-148. PubMed ID: 30328674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Technical Note: Treatment planning system (TPS) approximations matter - comparing intensity-modulated proton therapy (IMPT) plan quality and robustness between a commercial and an in-house developed TPS for nonsmall cell lung cancer (NSCLC).
    Liu C; Yu NY; Shan J; Bhangoo RS; Daniels TB; Chiang JS; Ding X; Lara P; Patrick CL; Archuleta JP; DeWees T; Hu Y; Schild SE; Bues M; Sio TT; Liu W
    Med Phys; 2019 Nov; 46(11):4755-4762. PubMed ID: 31498885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploratory Study of 4D versus 3D Robust Optimization in Intensity Modulated Proton Therapy for Lung Cancer.
    Liu W; Schild SE; Chang JY; Liao Z; Chang YH; Wen Z; Shen J; Stoker JB; Ding X; Hu Y; Sahoo N; Herman MG; Vargas C; Keole S; Wong W; Bues M
    Int J Radiat Oncol Biol Phys; 2016 May; 95(1):523-533. PubMed ID: 26725727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility study: spot-scanning proton arc therapy (SPArc) for left-sided whole breast radiotherapy.
    Chang S; Liu G; Zhao L; Dilworth JT; Zheng W; Jawad S; Yan D; Chen P; Stevens C; Kabolizadeh P; Li X; Ding X
    Radiat Oncol; 2020 Oct; 15(1):232. PubMed ID: 33028378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dosimetric comparison of distal esophageal carcinoma plans for patients treated with small-spot intensity-modulated proton versus volumetric-modulated arc therapies.
    Liu C; Bhangoo RS; Sio TT; Yu NY; Shan J; Chiang JS; Ding JX; Rule WG; Korte S; Lara P; Ding X; Bues M; Hu Y; DeWees T; Ashman JB; Liu W
    J Appl Clin Med Phys; 2019 Jul; 20(7):15-27. PubMed ID: 31112371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limited Impact of Setup and Range Uncertainties, Breathing Motion, and Interplay Effects in Robustly Optimized Intensity Modulated Proton Therapy for Stage III Non-small Cell Lung Cancer.
    Inoue T; Widder J; van Dijk LV; Takegawa H; Koizumi M; Takashina M; Usui K; Kurokawa C; Sugimoto S; Saito AI; Sasai K; Van't Veld AA; Langendijk JA; Korevaar EW
    Int J Radiat Oncol Biol Phys; 2016 Nov; 96(3):661-9. PubMed ID: 27681763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Spot Size and Spacing on the Quality of Robustly Optimized Intensity Modulated Proton Therapy Plans for Lung Cancer.
    Liu C; Schild SE; Chang JY; Liao Z; Korte S; Shen J; Ding X; Hu Y; Kang Y; Keole SR; Sio TT; Wong WW; Sahoo N; Bues M; Liu W
    Int J Radiat Oncol Biol Phys; 2018 Jun; 101(2):479-489. PubMed ID: 29550033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Technical Note: 4D robust optimization in small spot intensity-modulated proton therapy (IMPT) for distal esophageal carcinoma.
    Feng H; Shan J; Ashman JB; Rule WG; Bhangoo RS; Yu NY; Chiang J; Fatyga M; Wong WW; Schild SE; Sio TT; Liu W
    Med Phys; 2021 Aug; 48(8):4636-4647. PubMed ID: 34058026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Energy layer optimization strategies for intensity-modulated proton therapy of lung cancer patients.
    Jensen MF; Hoffmann L; Petersen JBB; Møller DS; Alber M
    Med Phys; 2018 Oct; 45(10):4355-4363. PubMed ID: 30129041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An in-silico comparison of proton beam and IMRT for postoperative radiotherapy in completely resected stage IIIA non-small cell lung cancer.
    Berman AT; Teo BK; Dolney D; Swisher-McClure S; Shahnazi K; Both S; Rengan R
    Radiat Oncol; 2013 Jun; 8():144. PubMed ID: 23767810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Organ sparing potential and inter-fraction robustness of adaptive intensity modulated proton therapy for lung cancer.
    van der Laan HP; Anakotta RM; Korevaar EW; Dieters M; Ubbels JF; Wijsman R; Sijtsema NM; Both S; Langendijk JA; Muijs CT; Knopf AC
    Acta Oncol; 2019 Dec; 58(12):1775-1782. PubMed ID: 31556764
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of photon volumetric modulated arc therapy, intensity-modulated proton therapy, and intensity-modulated carbon ion therapy for delivery of hypo-fractionated thoracic radiotherapy.
    Chi A; Lin LC; Wen S; Yan H; Hsi WC
    Radiat Oncol; 2017 Aug; 12(1):132. PubMed ID: 28810881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spot scanning proton arc therapy reduces toxicity in oropharyngeal cancer patients.
    de Jong BA; Battinelli C; Free J; Wagenaar D; Engwall E; Janssens G; Langendijk JA; Korevaar EW; Both S
    Med Phys; 2023 Mar; 50(3):1305-1317. PubMed ID: 36373893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potentials of robust intensity modulated scanning proton plans for locally advanced lung cancer in comparison to intensity modulated photon plans.
    Stuschke M; Kaiser A; Pöttgen C; Lübcke W; Farr J
    Radiother Oncol; 2012 Jul; 104(1):45-51. PubMed ID: 22560714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosimetric and radiobiological impact of intensity modulated proton therapy and RapidArc planning for high-risk prostate cancer with seminal vesicles.
    Rana S; Cheng C; Zhao L; Park S; Larson G; Vargas C; Dunn M; Zheng Y
    J Med Radiat Sci; 2017 Mar; 64(1):18-24. PubMed ID: 27741379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of grid size on uniform scanning and IMPT plans in XiO treatment planning system for brain cancer.
    Rana S; Zheng Y
    J Appl Clin Med Phys; 2015 Sep; 16(5):447–456. PubMed ID: 26699310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensity-modulated proton therapy reduces the dose to normal tissue compared with intensity-modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIB non-small-cell lung cancer: a virtual clinical study.
    Zhang X; Li Y; Pan X; Xiaoqiang L; Mohan R; Komaki R; Cox JD; Chang JY
    Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):357-66. PubMed ID: 19660879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.